- Home
- PRME vs INBX Comparison
PRME vs INBX Comparison
Compare PRME & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- INBX
- Stock Information
- Founded
- PRME 2019
- INBX 2010
- Country
- PRME United States
- INBX United States
- Employees
- PRME N/A
- INBX N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- PRME Health Care
- INBX Health Care
- Exchange
- PRME Nasdaq
- INBX Nasdaq
- Market Cap
- PRME 191.7M
- INBX 178.5M
- IPO Year
- PRME 2022
- INBX 2020
- Fundamental
- Price
- PRME $2.99
- INBX $14.98
- Analyst Decision
- PRME Buy
- INBX Hold
- Analyst Count
- PRME 6
- INBX 1
- Target Price
- PRME $9.38
- INBX N/A
- AVG Volume (30 Days)
- PRME 3.3M
- INBX 82.4K
- Earning Date
- PRME 08-04-2025
- INBX 08-12-2025
- Dividend Yield
- PRME N/A
- INBX N/A
- EPS Growth
- PRME N/A
- INBX N/A
- EPS
- PRME N/A
- INBX 111.58
- Revenue
- PRME $3,846,000.00
- INBX $200,000.00
- Revenue This Year
- PRME $104.12
- INBX N/A
- Revenue Next Year
- PRME $196.78
- INBX N/A
- P/E Ratio
- PRME N/A
- INBX $0.13
- Revenue Growth
- PRME 550.76
- INBX N/A
- 52 Week Low
- PRME $1.11
- INBX $10.80
- 52 Week High
- PRME $6.75
- INBX $17.79
- Technical
- Relative Strength Index (RSI)
- PRME 77.87
- INBX 59.12
- Support Level
- PRME $2.28
- INBX $13.97
- Resistance Level
- PRME $2.78
- INBX $15.18
- Average True Range (ATR)
- PRME 0.30
- INBX 0.72
- MACD
- PRME 0.11
- INBX -0.07
- Stochastic Oscillator
- PRME 97.24
- INBX 55.21
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.